D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 136.5 SEK 1.49% Market Closed
Market Cap: 2.3B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Other Liabilities
kr4.6m
CAGR 3-Years
103%
CAGR 5-Years
105%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Other Liabilities
kr91.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Liabilities
kr357k
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Other Liabilities
kr102m
CAGR 3-Years
25%
CAGR 5-Years
15%
CAGR 10-Years
16%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Liabilities
kr2.9B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
26%
BioArctic AB
STO:BIOA B
Other Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.3B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
123.02 SEK
Overvaluation 10%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Other Liabilities?
Other Liabilities
4.6m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Other Liabilities amounts to 4.6m SEK.

What is Devyser Diagnostics AB's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
105%

Over the last year, the Other Liabilities growth was 136%. The average annual Other Liabilities growth rates for Devyser Diagnostics AB have been 103% over the past three years , 105% over the past five years .

Back to Top